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ABSTRACT 
COGNITIVE DECLINE AND POLYPHARMACY IN AN ELDERLY 
POPULATION 
Ximena A. Oyarzún González 
March 20, 2014 
 
Aging is associated with increased risk of chronic disease, comorbidities, and 
greater medication use.  Polypharmacy, the concomitant use of 5 or more medications, 
has been associated with adverse health effects, and potentially cognitive decline.  The 
proposed hypothesis is that polypharmacy increases the risk of cognitive decline in 
elderly people. 
Using longitudinal data from 572 participants from the New Mexico Aging 
Process Study cohort, the impact of polypharmacy on the Mini Mental State Examination 
(MMSE) scores and Mild Cognitive Impairment (MCI) was studied.  The statistical 
analyses were performed using mixed linear regression multivariable models and 
generalized estimating equations, adjusting for important covariates. 
Polypharmacy was associated with a 0.11±0.09 decrease in MMSE scores (p-
value=0.23) and an increased risk of MCI (odds ratio=1.95, 95% CI 0.40-9.43).  The 
results suggest that polypharmacy may increase the rate of cognitive decline in elderly 
people.  Larger studies in other populations are needed to support this hypothesis.   
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The Department of Health & Human Services estimates that by 2030 there will be 
72.1 million individuals 65 years of age or older in the United States, an estimate that is 
more than twice the number of older people in 2000.[1]  According to the last US Census, 
there are 672,095 persons 60 and older in the Commonwealth of Kentucky, and it is 
expected that by 2030 this number will increase to 1,287,999, or 26% of the population.[2] 
Furthermore the life expectancy for the general US population born during 2008 
was 78.1 years, and 75.6 and 80.5 years for males and females respectively.[3]  In 
addition, from this same analysis, it was established that the life expectancy for 65 year 
old people in US for 2008 was 18.78 years; in other words, we can expect that a person 
65 years of age in 2008 will live until about 85 years of age.[3]  There are also differences 
in life expectancy by race; the life expectancies for Hispanics are 80.9 years, 78.37 years 
for non- Hispanic whites, 74.03 years for blacks, and 73.70 years for non-Hispanic 
blacks.[3]   
There are several anatomical and physiological changes associated with aging that 
increase the probability of adverse reactions to commonly used drugs.  Some of these 
changes include a decrease in saliva production, atrophy of gastric mucosa and 
muscularis mucosae, decrease in stomach acid production, decrease in liver size and 
blood flow, decrease in creatinine clearance and glomerular filtration rate, changes in the 
body fat composition, among others.[4]  These changes and the increased need of 
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treatments due to the presence of chronic diseases, may increase the risk of experiencing 
adverse drug reactions (ADR), drug-drug interactions and drug-disease interactions, 
particularly due to the physiological changes related with age, such as changes in 
absorption, distribution, metabolism and excretion of the drugs.[5]   
When adverse drug reactions occur in older people, they are more likely to be 
severe and less likely to be recognized or reported by the patient.  In addition it has been 
described that the incidence of adverse drug reactions correlates with age, and can cause 
death in 18% of older hospitalized patients.[5]  Furthermore, considering all the factors 
that are most consistently associated with ADR, polypharmacy is considered the most 
important.[5] 
POLYPHARMACY AND POTENTIALLY INAPPROPRIATE PRESCRIBING 
Polypharmacy has been defined in several different ways, but the most common 
definition is the simultaneous use of five or more medications.[6-8]  Literature described 
that the prevalence of polypharmacy is between 5% to 78%, wherein the variation 
depends on the definition used and the sample studied.[6]  Kaufman et al (2002) analyzed 
the data from The Slone Survey between 1998 and 1999, describing that 57% of 
American women aged 65 years or older took at least five medications, and 12% took at 
least 10 medications.[9]  Nobili et al. studied the prevalence of polypharmacy in the 
Lombardy Region of Italy among 1,915,579 people aged 65 years or older (1,767,239 
included in the analysis) living in that region, and found that 88% of the elderly 
population received at least one drug prescription, and 46% received five or more 
drugs.[10] 
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Over time, several criteria have been developed to evaluate the appropriateness of 
prescribing in elderly people.  One of those criteria, and the most widely used are the 
Beers Criteria, which defines Potentially Inappropriate Medication (PIM) as those 
medications that are thought to offer inadequate benefits or to pose so much risk to older 
persons that they are rarely appropriate to prescribe.[11]  Beers Criteria are explicit criteria 
used to determine inappropriate medication use, originally applied in nursing homes for 
quality assurance, health service research and clinical practice guidelines.[11]  Since 1991, 
several updates and modifications of the original Beers criteria have been published, 
including the last update of 2012.[12]   
This last update was performed by the American Geriatric Society by a panel of 
11 experts in the field, who reviewed and graded different evidence to develop the final 
criteria.  The final criteria comprises 3 categories: PIM and classes to avoid in older 
adults, PIM and classes to avoid in older adults with certain diseases and syndromes that 
the drugs listed can exacerbate, and finally medication to be used with caution in older 
adults.[12]  This update was designed to be used in all ambulatory and institutional settings 
of care for populations aged 65 and older in the United States.[12] 
In addition to Beers Criteria, a new screening tool has been developed and is 
called STOPP (Screening Tool of Older Person’s Potentially Inappropriate Prescriptions).  
In this case, a panel of experts analyzed 68 potentially inappropriate prescribing practices 
in older people, from which they included 65 in the final STOPP.[13]  STOPP criteria 
include different instances such as drug-drug and drug-disease interactions, drugs which 
adversely affect older patients at risk of falls and duplicate drug prescriptions.[13] 
 
 4  
In a study comparing both methods for defining PIM, Gallagher et al. conclude 
that STOPP identified significantly more PIMs than Beers criteria (2003 version) in 
acutely ill older patients.  However, they made strong emphasis in that Beers criteria may 
not be suitable to be used outside the US, mostly because many of the drugs present in 
the Beers’ criteria are rarely used in Western Europe.[13] 
Among the drugs that have been associated with adverse events, cognitive decline 
and loss of independence are the anticholinergics.[14]  This association is supported by the 
ample evidence showing that drugs with anticholinergic properties are especially likely to 
cause adverse events leading to cognitive impairment, cognitive decline, delirium, falls 
and loss of independence.[14, 15]  Anticholinergics may affect the brain by blocking the 
neurotransmitter acetylcholine, and older people are more susceptible to these effects due 
to the age-related changes.  The changes that are mostly related with the increased 
susceptibility to anticholinergics are a decrease in cholinergic neurons or receptors in the 
brain, a reduction in hepatic and renal clearance of drugs, and an increase in blood barrier 
permeability, especially during acute diseases.[14] 
One way to evaluate the potential risk at which the patients are exposed when 
using anticholinergics is using the Anticholinergic Cognitive Burden (ACB), which is a 
scale designed to identify the severity of any anticholinergic effect on cognition.  In this 
case, anticholinergic drugs are scored according to the anticholinergic effect, thus drugs 
with established clinically relevant cognitive effects are scored with 2 or 3, and those 
with serum anticholinergic activity or in vitro affinity for muscarinic receptors but with 
not known clinically relevant cognitive effect are scored with one.[14]  Another tool to 
evaluate the risk associated with the use of anticholinergics is the Anticholinergic Risk 
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Scale (ARS), which is a tool designed to estimate the extent to which an individual 
patient may be at risk of anticholinergic adverse effects that can lead to some kind of 
cognitive dysfunction.  In this scale, medications are divided in three categories, 
moderate anticholinergic potential (1 point), strong anticholinergic potential (2 points), 
and very strong anticholinergic potential (3 points).[14, 15] 
Pasina et al. performed a study among elderly patients admitted in an Italian 
internal medicine or geriatric ward analyzing the use of drugs with anticholinergic 
properties and the cognitive and functional performance.  In this study, cognitive 
performance was measured using short blessed test (SBT, higher scores indicate worse 
cognition) and functional performance was evaluated using Barthel Index (BI, higher 
scores indicate better functional performance, 100 being the maximum).  The authors 
concluded that patients receiving drugs with anticholinergic properties have a mean SBT 
score of 8.9 (95% CI 8.4-9.3) which was significantly different from the mean SBT of 7.8 
(95% CI 7.2-8.4;p=0.006) obtained by the patients not receiving drugs with 
anticholinergic properties.[14]  Furthermore, Pasina et al. described that the patients 
treated with anticholinergic drugs have a mean BI of 82.4 (95% CI 80.8-84.0), which is 5 
points lower than the 87.8 points (95%CI 85.9-89.7;p=<0.0001) obtained by the patients 
receiving no anticholinergic medication.[14] 
In a follow-up study performed in Finland by Jyrkkä et al., a population of 294 
elderly people was followed between 2004 and 2007, recording the use of medications 
and the cognitive function of participants.[16]  Regarding polypharmacy, they observed 
that from 294 participants, 154 (52.4%) were using at least 6 medications concomitantly 
in 2004, and that by 2007 the number of participants using 6 or more medications 
 
 6  
increased to 192 (65.3%).  Furthermore, the authors observed that excessive 
polypharmacy, defined as the concomitant use of 10 or more medications, was associated 
with a decline in the cognitive capacity measured by MMSE (mini-mental state 
examination) compared with the non-polypharmacy group.[16]  In particular, they 
observed that from the 154 with polypharmacy (5 or more concomitant medications), 60 
(38.96%) had impaired cognition at baseline, and at follow up, from the 192 participants 
with polypharmacy, 87 (45.31%) were found to have impaired cognition.[16]  In 
particular, they observed that the group with excessive polypharmacy had lower MMSE 
scores at baseline compared with the non-polypharmacy group (p=0.020) and that this 
difference remained significant over the three-year follow up (p<0.001).[16]  
COGNITIVE IMPAIRMENT 
It has been estimated that without changes in mortality or new effective 
prevention strategies or curative treatments, the number of affected people with dementia 
will double every 20 years reaching 81.1 million people by 2040.[17]  Mild cognitive 
impairment (MCI) or Cognitive Impairment non dementia (CIND)[18] is a syndrome 
defined as cognitive decline greater than that expected for an individual’s age and 
education level but that does not interfere notably with activities of daily life.[19]  In 
addition, it differs from dementia, in that the cognitive impairment in dementia is more 
severe and widespread and has a substantial effect on daily function.[19]  However, it has 
been described that a percentage of the cases of MCI evolve to dementia or Alzheimer’s 
Disease (AD) [19, 20], which emphasizes the importance of studying MCI.  
In general terms, Gauthier et al. described in 2006 that previous studies described 
a prevalence of MCI in the general elderly population between 3% and 19%, with an 
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incidence of 8-58 per 1000 per year, and a risk of developing dementia of 11-33% over 2 
years.[19] 
In a more recent study, Plassman et al. used the data from the “Aging, 
Demographics and Memory Study (ADAMS study)”, which is a longitudinal study that 
includes individuals from all regions in the US, to estimate the incidence of CIND and 
the progression of CIND to dementia during the follow up period.[18]  The researchers 
found that the amount of participants who evolved to dementia from CIND was less than 
50%.[18]  Their results indicated that the incidence of CIND is 60 cases per 1,000 person-
years.[18]  
Factors that affect cognition are depicted below in a directed acyclic graph (Figure 
1).  In the studies performed regarding MCI, it has been found that higher age, history of 
a diagnosis of hypertension, ethnicity and lower education are significant risk factors in 
the development of the condition.[17, 21]  In a study performed in elderly women in which 
lifestyle factors and comorbidities were evaluated regarding the development of cognitive 
impairment, results concluded that lifestyle risk factors, comorbid disorders and genetic 
factors contribute to the development of age-related cognitive impairment.[22]  In 
particular, Rasmusssen et al. noticed that obesity and depression were significantly 
associated with cognitive impairment, with OR values of 1.54 (95% CI=1.00-2.36) and 3 
(95% CI=1.28-7.06), respectively.[22] 
Deficits in executive function, as compared to other cognitive domains, have been 
associated with decrease status and decrease ability for older individuals to carry out 
activities of daily living.[23]  Thus, cognitive impairment and dementia are strong 
predictors of incident disability.[24]  Among other factors that can be associated with 
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cognitive impairment, it has been described that higher years of education may have a 
protective effect on cognitive decline.[17]  Related with education, it has been described 
that lower SES is associated with higher risk of MCI or CIND.  Sattler et al. studied the 
differential effect of cognitive leisure activities, education and socioeconomic status on 
the development of MCI and Alzheimer’s disease using a cohort recruited for the ILSE 
(German acronym for Interdisciplinary Longitudinal Study of Adult Development) study, 
which is comprised by people born between 1930 and 1932, and doing 12 years of follow 
up.[25]  Their results show that high SES was associated with a 69% reduced risk of 
developing MCI/AD compared with low SES (OR=0.31, 95%CI 0.14-0.73, p<0.01).[25] 
Smoking and alcohol consumption have also been found to be associated with 
cognitive impairment, however, these associations are still ambiguous.[26]  Okusaga et al. 
studied the possible connection between cardiovascular risk factors, such as smoking, and 
cognitive function.  Their results shown that being a smoker was significantly associated 
with worse cognitive performance on all the cognitive function tests performed (MMSE, 
Trail making test, digit symbol substitution, among others) except for the verbal fluency 
test.[27]  Furthermore, Huang et al. studied the association of cognitive impairment with 
different habits such as smoking in a population of Chinese 90 years and older.  
However, their results show that current smoking habits had a significant OR for 
cognitive impairment only among men (2.1, 95% CI=1.2-4.0).[28]  Supporting the lack of 
association between smoking and cognitive impairment in women, Rasmussen et al., who 
studied cognitive impairment among elderly women, found that smoking was not 
significantly associated with cognitive impairment.[22] 
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It has been described that heavy drinking may induce cerebral blood flow 
reduction, brain shrinkage, neuron apoptosis, and synapse loss, all of which may lead to 
evident cognitive decline.[29]  However, research has also shown that light moderate 
alcohol use may reduce the risk for cognitive impairment.[29]  Rasmussen et al. found that 
consumption of alcohol, particularly medium to moderate consumption, was associated 
with a decreased risk of cognitive impairment (p=0.01) and that the relation between 
amounts of alcohol consumed and risk for cognitive impairment produced a U-shaped 
curve.  Xu et al. found that moderate drinkers, defined as those who had consumed no 
more than two drinks a day for at least 6 months, had the smallest decrease of MMSE 
score (2.9±4.0) and heavy drinkers, defined as those who consumed more than two drinks 
a day for more than 6 months, had the largest decrease in MMSE score (8.6±6.6) during a 
2 year follow up study.[29] 
It has also been described that an increased number of comorbidities is associated 
with increased risk of cognitive impairment.  Gallucci et al. in a longitudinal study 
following the elderly population of the municipality of Treviso, Italy, found that an 
increased Charlson Comorbidity index was associated with a decline in cognitive 
function (univariate analysis with a p-value =0.008)[30]  However, additional research has 
shown that specific diseases are independently associated with cognitive impairment.  
Among these diseases are hypertension [26, 31], depression [31, 32] and diabetes.[26] 
Regarding the association between hypertension and cognitive decline, cross-
sectional studies have reached divergent results, while most longitudinal studies 
performed have demonstrated a significant association between hypertension and 
cognitive decline.[26]   
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Depression, as mentioned before, has also been independently associated with 
mild cognitive impairment and dementia.  Several studies have shown that subjects with 
depression had higher risk of cognitive decline or of developing any dementia.[31-33]  One 
of this studies (Scuteri et al), was a cross-sectional study of 6180 Italian elderly patients 
admitted to a hospital network.  They found that patients with depression have an OR of 
2.70 (95% CI 2.33-3.13, p-value= 0.002) for cognitive impairment compared with not 
depressed patients, and that patients with depression and hypertension have an OR of 
2.69 (95% CI 2.21-3.29, p-value= 0.001) of having cognitive impairment compared with 
normotensive non depressed patients.[31]  On the other hand, Scuteri et al., also found that 
patients with depression and with depression and hypertension have an OR of 2.71 (95% 
CI 2.34-3.13, p-value= 0.001) and 1.95 (95% CI 1.59-2.40, p-value= 0.001) of having a 
lower functional independence regarding the non-depressed patients and those 
normotensive and non-depressed patients.[31] 
A diagnosis of diabetes mellitus has also been independently associated with 
increased risk of cognitive impairment.[26]  Recent studies have demonstrated that longer 
duration of diabetes, lack of anti-diabetic medication, and higher number of 
hypoglycemic episodes were associated with an increased risk of cognitive decline.[26] 
Physical activity has been associated as a protective factor against cognitive 
impairment in elderly.[26]  Hung et al., who studied the impact of lifestyle habits on 
cognitive function of Chinese people 90 years and older, found that current exercise was 
a protective factor against cognitive impairment (unadjusted OR 0.337, 95%CI 0.180-
0.675 for men).[28]  Rassmussen et al. found that among women exercise has a dose-
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dependent and inverse relationship with cognitive impairment, with an OR for the group 
that exercises of 0.54 (95% CI=0.37-0.81) regarding the group that doesn’t.[22] 
Another association that is worth analyzing is the one between Body Mass Index 
(BMI) and cognitive impairment.[30]  One of this studies showed that women with a BMI 
of 27.5 or greater have an OR of 1.54 (95%CI=1.00-2.36, p=0.04) of having cognitive 
impairment that women with lower BMI.[22]  Furthermore, Galluci et al. found that higher 
BMI acts as a protective factor against cognitive impairment, however, they also found 
that the interaction between BMI with age was significant, and that the positive effect of 
the high BMI decreased as the age of the individual increased.[30] 
Finally, Apolipoprotein E (APOE) is a glycoprotein involved in the transport of 
cholesterol and lipids through cell membranes, and it is thought to be involved in cell 
growth and neuronal regeneration in the brain.[34, 35]  The APOE genotype has 3 
polymorphisms determined by 3 alleles, 2, 3 (the most common and the one considered 
as the normal polymorphism) and 4.[34-38]  From these 3 polymorphisms, the presence of 
allele 4 has been associated with a higher risk of mortality, cardiovascular disease, AD, 
dementia and cognitive decline, among other adverse effects.[37, 39, 40]  On the other hand, 
allele 2 has been associated with decreased risk of mortality, dementia and levels of 
cholesterol.[40, 41]   
All the age-related changes mentioned above, as well as the use of different and 
multiple inappropriate drugs in elderly patients, can affect the cognitive status of an 
elderly person in the different cognitive domains also affecting the functional 
independence of that person.[24]. 
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The loss of functionality and cognitive decline will come with an increase in the 
cost of living and healthcare for this population.  According to the published data it is 
estimated that by 2030, the population 65 and older will represent 20% of the US 
population and 50% of healthcare costs. [7]   
Considering the dearth of scientific studies analyzing the effects of polypharmacy 
and potentially inappropriate medications on cognitive decline, and particularly in the 
American population, this study seeks to use previously collected data to further 
investigate the effects of these exposures and other possible factors on cognitive status 
changes. 
 



















The population studied is a subset of the New Mexico Aging Process Study 
(NMAPS), which was initiated in 1979 as a longitudinal study of nutrition and aging. The 
study annually monitored the nutritional status of participants through measurements of 
dietary intake, biochemical parameters, anthropometry, body composition and cognitive 
and functional status.[42] 
The inclusion criteria for the NMAPS was that the study subjects must be 60 or 
older, free of major medical conditions, and living independently[43].  This population 
was defined as “healthy” because the participants did not present clinical conditions and 
were not taking prescription medication with 2 exceptions, specifically thyroid 
replacement therapy and antihypertensive medication to control systolic blood pressure 
initially <180 mm Hg or diastolic pressure <100 mm Hg.[44]  These inclusion criteria 
were only applied to the subjects when entering the study, and NMAPS participant were 
not required to maintain good health to continue in the study.  Exclusion criteria include 
serious clinical conditions, such as recent myocardial infarction, significant peripheral 
vascular disease, insulin-dependent diabetes, hepatic disease, history of cancer requiring 
surgery, radiotherapy or chemotherapy in the past 10 years and untreated hypertension.[45] 
NMAPS was initiated with the recruitment of 303 volunteers to participate in a 
study examining the relationship between nutrition and immune function, and this 
subsequently evolved into a multidisciplinary, longitudinal study examining the impact of 
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nutrition on resultant changes in body composition and organ function in relation to the 
aging process and health status of the elderly.[44]  During the study, new recruits replaced 
those who may have died or dropped from the study.[45]  
NMAPS subjects were seen annually at which time they underwent assessment 
for cognitive, sensory and physical function (including blood sampling), health habits and 
attitudes, morbidity, falls, dietary intake, physical activity, body composition and 
nutritional status.[45]  Information on health status and comorbidities were ascertained by 
physical examination (including pulse, blood pressure, height and weight 
measurements[45]) and medication use.[46]  Cognitive function was assessed using Mini 
mental state examination (MMSE), the geriatric depression scale (GDS), Wais R digit 
span, Fuld object memory evaluation, Color trails 1 and 2 and clock drawing[45].  
Apolipoprotein E genotype was assessed using restriction fragment length polymorphism 
analysis of polymerase chain reaction products.[47] 
Since 1980 approximately 40 subjects developed Alzheimer’s disease or other 
dementia and follow up was discontinued because it was no longer possible to obtain 
competent informed consent.[45]  The average dropout rate was 4.2% per year.[45] 
In order to fulfill the objectives of the present study, data were utilized from 
participants who had cognitive evaluations, particularly, those participants for who the 
MMSE scores were available.  Data from participants whose information regarding 
education was missing were excluded from the analysis.  The same was done for those 
participants for whom the information regarding polypharmacy was missing. Thus, the 
final sample consisted of 572 participants, and 2955 observations. 
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II. Exposure variable(s) assessment and definition 
Polypharmacy was defined as the concomitant use of 5 or more medications.  The 
evaluation consists of the simple count of prescribed and over the counter (OTC) 
medications.  Medications were self-reported during each year the participant was 
interviewed.  Therefore an individual may be classified as having polypharmacy some 
years but not others in this longitudinal dataset. 
III. Outcome variable(s) assessment and definition 
The changes in cognitive function were evaluated using the Mini Mental State 
Examination.  The MMSE is a short test that evaluates the different domains of cognition 
and is a simplified, scored form of the cognitive mental status examination [38].  The 
MMSE includes 11 questions, and requires 5 to 10 minutes to administer [48].  It was 
designed to concentrate only on the cognitive aspects of mental function, excluding 
questions concerning mood, abnormal mental experiences and the form of thinking [48]. 
Between the years of 1989 and 1993, the standardized version of the MMSE was 
applied, however between 1994 and 2003 a modified MMSE was applied in NMAPS.  
Therefore, data were cleaned and recoded where necessary to conform to the 
standardized Mini-Mental State Evaluation [48]. 
Literature described a cutoff score between 22 and 25 for people with more than 8 
years of education to define cognitive impairment. [49, 50]  For this reason, the cutoff score 
to define MCI in the present study was a MMSE score ≤ 23 points. 
IV. Covariate assessment and definitions 
The covariates that were analyzed to minimize confounding include sex, ethnicity, 
marital status, housing, working status, education level, Charlson Comorbidity Index, 
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presence of hypertension, presence of diabetes, presence of depression, presence of 
APOE 4 allele and BMI.  These were selected because have been previously associated 
with cognitive decline, mild cognitive impairment and/or polypharmacy. [16, 25, 30, 33] 
The Charlson Comorbidity Index[51] was used to categorized the health status of 
the patients.  The data were categorized as follows: 
 Charlson comorbidity Index=0 
 Charlson comorbidity Index=1 
 Charlson comorbidity index ≥2 
This categorization was made based on the sample distribution, and considering 
that the number of participants with a Charlson index score of 2 or more was small, they 
were all grouped in one category. 
In addition to the above, as a second covariate to evaluate health status, we used 
living situation, which was defined as a dichotomous variable in which the participant 
was or was not institutionalized. 
Education was analyzed as a categorical covariate.  The participants were asked 
for their highest level of education.  The data were divided in the following categories:  
 12 or less years of education 
 between 12 and 16 years of education 
 more than 16 years of education 
The presence or absence of Apolipoprotein E 4 allele in the participants was also 
included as a covariate, because as mentioned before, it has been associated with higher 
risk of AD and cognitive decline.  The covariate was analyzed as a dichotomous variable, 
considering the presence or absence of at least one 4 allele  
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Hypertension and diabetes were treated as a dichotomous variable, evaluating the 
presence or absence of the diagnosis.  Diagnosis data was obtained from participant’s 
self-report and physical examination.[46] 
Depression was assessed in two ways.  The GDS was applied during the NMAPS; 
in this case the variable was defined as dichotomous where if the GDS score was greater 
or equal than 5 the participant was considered depressed.  The second was using the 
presence or absence of a depression diagnosis according to the medical history obtained 
by interviewing the participant. 
It has been described that greater involvement in physical, intellectual and social 
activities have a protective role in the development of MCI.[52]  In order to evaluate the 
participation of the study subjects in these activities, the working status covariate was 
used.  This was defined as a dichotomous variable in which the participant was employed 
or doing volunteer jobs at the moment of the interview or not.   
The NMAPS categorized marital status as married, divorced, widowed or never 
married.  However the number of subjects in all the categories except “married” was 
small, therefore, all the categories that implied that the participant was alone (i.e., 
divorced, widowed or never married) were merged together in one category.  Therefore, 
marital status was analyzed as a dichotomous covariate. 
Body mass index (BMI) was categorized as follows, according to the categories 
defined by the World Health Organization (WHO): 
 BMI < 25 (normal weight)  
 25≤BMI<30 (overweight) 
 BMI≥ 30 (obese)  
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V. Statistical Analyses  
To compare the unadjusted differences between groups of participants with and 
without polypharmacy, T-tests were applied for continuous variables and 2 for 
categorical variables.  When a cell count is smaller than 5, Fisher’s exact test was 
applied. 
The data from the study are longitudinal, and therefore data were collected over a 
span of several years for each participant (range: 1 to more than 10 years). To account for 
the correlation of measurements across time within each subject, a random effects mixed 
model was used, with a random effect for subject.  This mixed linear model was used to 
evaluate the hypothesis described above as well as include the mentioned covariates as 
fixed factors or effects. 
In order to define which covariates should be included in the model, a model was 
run including all the covariates and removing one at a time and if the change in the 
estimate for polypharmacy was greater than a 10% then the covariate was included in the 
final model. 
The covariates diabetes, depression and housing were not included in the 
covariate assessment process because the sample sizes were not adequate. 
The mixed effects model was implemented using the SAS Proc Mixed procedure, 
which can perform linear regression for longitudinal data using both fixed and random 
effects.  MMSE scores were modeled as a function of presence or absence of 
polypharmacy as well as covariates including age at baseline, years since baseline, and 
other covariates as determined by the covariate selection process above.  
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Generalized estimating equations (GEE) were applied using the SAS Genmod 
procedure, which allows regression of dichotomous outcomes for repeated measures, 
considering the correlation of multiple observations within subjects.[53] 
VI. Power calculations 
The power to detect an association between polypharmacy and MCI was 62.74%, 
considering the following: 
 Cohort study design 
 Total sample population of 572 for the analysis of polypharmacy 
 Alpha level of 0.05 
 An exposure to polypharmacy of 39.5% 
 A risk of MCI of 3.98% among those exposed to polypharmacy; and 
 A risk of MCI of 8.96% among those unexposed to polypharmacy 
The power to detect a difference of 1 point in the means between the MMSE 
scores at the first and last evaluation is >99%, and to detect a difference of 0.5 points is 
91.04%, taking into consideration the following: 
 Sample size of 572 individuals 
 Variance for MMSE score at baseline of 4.75 
 Variance of MMSE score at endpoint of 8.35 
The power calculations were conducted using OpenEpi software.[54] 
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RESULTS 
I. Population characteristics 
Most of the study subjects were female (63.6%), white (88.5%), and married 
(66.6%) (Table 1).  In addition, 47.2% of the study population had between 12 and 16 
years of education and 36.2% had more than 16 years of education.   
The average number of medications for the population was 2.4 at first evaluation 
and 4.1 at the last evaluation; however the number of medications ranged from 0 to 16 
and the prevalence of polypharmacy at baseline and endpoint was 14% and 40%, 
respectively.  The overall prevalence of MCI in the study population was 4.6% and 7% at 
baseline and endpoint, respectively (Table 2). 
From a comorbidity perspective, the majority of the sample studied was non- 
diabetic, normotensive, non-depressed (although the GDS scores indicated that most of 
the sample have depressive symptoms), had normal weight and a Charlson comorbidity 
index of 0, which indicated that the majority of participants of this study were generally 
healthy (Table 2). 
Participants with polypharmacy were mostly women with normal weight, had 
between 12 and 16 years of education and had a Charlson comorbidity index higher than 
0.  Furthermore, the majority of the participants with polypharmacy were not diagnosed 
with depression nor hypertension (Table 3). 
In the same way, participants with MCI represent a small percentage of the 
sample, and they were mostly females with normal BMI, had more than 12 years of 
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education, did not have hypertension, and had a Charlson comorbidity index equal or 
higher than 2 (Table 4). 
II. Covariate assessment results  
The results of the covariate assessment indicated that sex, presence or absence of 
APOE 4 allele, BMI, presence or absence of hypertension, and Charlson index were 
confounding covariates, and therefore, should be included in the multivariable models. 
III. Unadjusted analyses 
The bivariate analysis shows that the group with polypharmacy had a significantly 
higher MMSE score than those with no polypharmacy at baseline and at the final 
evaluation.  There was no significant difference in the change of the MMSE score 
between those with polypharmacy and those without it (Table 5).   
The association between MCI and polypharmacy was significant both at baseline 
and the endpoint evaluation; however when looking at the sample distribution, MCI was 
more common among those with no polypharmacy than among those with polypharmacy 
(Table 5). 
Furthermore, the analysis of the MMSE scores among those who changed 
polypharmacy status from non-polypharmacy to polypharmacy, compared with those 
who didn´t change polypharmacy status was significant, showing a higher MMSE score 
for those who changed status to polypharmacy (Table 6). 
IV. Adjusted Analyses 
When the mixed multivariable-adjusted model was run, polypharmacy was 
associated with a decreased MMSE score, although the association was not statistically 
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significant.  Age at baseline was associated with a significant decrease in the MMSE 
score by 0.047 points per each additional year of age.  Furthermore, a higher Charlson 
comorbidity index was significantly associated with a lower MMSE score, while the 
presence of hypertension was significantly associated with a higher MMSE score (Table 
7). 
Consistent results were observed when the outcome was replaced by the change in 
the MMSE score (MMSE at final evaluation – MMSE at baseline). Age and a higher 
Charlson comorbidity index were significantly associated with a higher decline in the 
score and hypertension was associated with a lower decline in the MMSE score. (Table 
8) 
In the analysis of MCI as an outcome, the direction of the estimates were 
consistent with the MMSE analysis (Table 9). 
  
 
 23  
 
DISCUSSION 
The analysis performed showed a high prevalence of polypharmacy in a relatively 
healthy population, but a low prevalence of mild cognitive impairment. Polypharmacy 
was associated with lower MMSE scores in this population, and although the association 
was not statistically significant, the direction of effect suggests that polypharmacy could 
be an important factor in cognitive decline. Other notable findings include the effects of 
male gender, Charlson comorbidity index greater than 0 and the presence of APOE 4 
allele on cognitive decline, even though only Charlson comorbidity index reach statistical 
significance.  Furthermore, hypertension was significantly associated with higher MMSE 
scores.  These results were consistent with the analyses done for both MCI and for 
change in MMSE score over time. 
The prevalence of polypharmacy increased over the follow-up period, and this 
was positively associated with an increase in the MCI rates, although the association did 
not reach statistical significance.  However, a very low proportion of the sample did have 
both polypharmacy and MCI (0 and 1.57% at baseline and endpoint, respectively), which 
is reflected in the power to detect this association (62.74%), leaving a 37.26% chance of a 
type II error, if there is truly an association.  Similarly, the MMSE scores were 
significantly higher in participants with polypharmacy than participants without 
polypharmacy both at baseline and at the endpoint evaluation (p-value= 0.009 and 0.0002 
respectively).  A reason for this may be that participants with polypharmacy have higher 
basal and final MMSE scores than participants without polypharmacy, however patients 
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with polypharmacy have a more pronounced decreased in the MMSE score over the 
follow up period than participants without polypharmacy.  
When comparing the results from the unadjusted versus the adjusted analysis, it is 
possible to observe that the association between polypharmacy and MMSE scores are in 
the opposite direction; while the unadjusted cross-sectional analyses both at baseline and 
at the final exam indicated that patients with polypharmacy have higher MMSE scores, 
the adjusted longitudinal analysis shows that polypharmacy is associated with a decrease 
in MMSE scores over time  This demonstrates the importance of considering a baseline 
MMSE score in order to evaluate the effect of an specific exposure, in this case 
polypharmacy, on the outcome of interest, in this case MMSE score, MMSE score 
change and MCI.   
The observed prevalence of MCI in the studied population was about 7% at the 
last evaluation performed, lower than the prevalence described by the literature which 
can be up to 20%.[19]  The low prevalence of MCI in this sample could be explained by 
the fact that higher education has been described as a protective factor for MCI and 
cognitive decline in elderly people[17, 25], and the sampled population was highly 
educated, with more than 80% of the sample having more than 12 years of education and 
36.19% having more than 16 years of education. 
The results obtained by the present study are consistent with those obtained by 
Jyrkka et al, whose study reported that polypharmacy and male sex are associated with a 
lower MMSE score[16].  Furthermore, the present study showed that a CCI equal or higher 
than 2 is significantly associated with lower MMSE scores and cognitive impairment, 
which is consistent with the results obtained from Scuteri et al, whose findings indicate 
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that the number and severity of comorbidities are negatively associated with cognitive 
impairment.[31] 
In the present study hypertension was found to be associated with significantly 
higher MMSE scores and smaller changes in MMSE scores, while previous studies have 
found that hypertension has a negative impact on cognitive performance.[27, 31]   However, 
it has been described that the treatment of hypertension can act as a protective factor for 
cognitive decline and MCI/dementia.  In a review done by Duron and Hanon (2008), it 
was described that even though hypertension has been positively correlated with 
cognitive decline and dementia, treated hypertensive subjects have a decreased in 
cognitive decline compared with those untreated.[55]  This is potentially consistent with 
the results obtained from the multivariable  regression models, wherein it was observed 
that hypertension was significantly associated with increasing MMSE scores and 
significantly decreasing MCI.  If the ‘non-hypertensive’ group in this study actually 
includes some individuals with undiagnosed hypertension, our study results would be 
consistent with those summarized by Duron and Hanon.  
From the results obtained it is possible to suggest that polypharmacy is a risk 
factor for cognitive decline and MCI; however further research regarding the drugs used 
by older people is necessary to establish whether the number of drugs the risk factor or if 
it is a specific drug or group of drugs the responsible for the cognitive impairment.  In 
this regard, it has been described that anticholinergic drugs and other drugs categorized as 
PIM are highly associated with cognitive impairment, whereas other categories of drugs 
have not shown an association. [56]  In this regard, it is important that future research take 
into consideration that drugs can have a negative or positive impact on the cognitive 
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performance of a subject by direct or indirect pathways, or not have any impact at all, 
which makes even more important not to study the drug use in this population only by the 
number of drugs used, but also by the type of drugs.  This approach may be potentially 
helpful in the clarification of confusing results, such as the ones obtained by the 
unadjusted analysis.  Furthermore, it is important to take into account that patients 
without polypharmacy may have undiagnosed and/or untreated diseases that are 
negatively impacting their cognitive performance. 
 In addition to the above, the impact of polypharmacy in an elderly patient will 
vary depending on the his/her physical condition, particularly because it is known that the 
process of absorption, distribution, metabolism and excretion, undergo modifications 
associated with aging, and this can complicate the ability of elderly people to clear the 
drugs they are receiving, with a different degree in each patient. However, the more drugs 
the patient is receiving, the more likely it is to observe an adverse drug event, such as 
cognitive impairment. [6, 7, 9]  This, is another important reason why future research should 
involves specific drug analysis, such as PIM, or ACB, into its aims. 
One of the strengths of the present study, is that due to the high homogeneity of 
the studied population, the internal validity of the study is high, decreasing the chances of 
bias or systematic error.[57]  Another strength of the study, was the availability of data 
from a longitudinal study with a long time span, which allows to evaluate the evolution of 
the cognitive performance of the study subjects.  Finally, the fact that the data available 
comprised data on APOE genotypes for most of the subjects as well as other covariates 
such as hypertension, BMI and education level, allowed the incorporation and analysis of 
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these covariates, minimizing confounding and allowing comparison with other studies 
that were also able to adjust for these factors.  
Part of the homogeneity of the population is the health status of the studied 
sample, where the prevalence of diabetes in the studied sample (0.53%) was much lower 
than the 26.9% prevalence described for Americans older than 65 years old.[58]  
Furthermore, the prevalence of hypertension in the studied sample was of 34.45% while 
the prevalence of hypertension described for Americans 65 or older is 71.6%.[59]  The 
prevalence of obesity observed was of 10.53% which is lower than the 35% of adults 65 
or older described for US population[60].  All this information demonstrates that the 
sampled population was unusually healthy compared with the general American 
population. 
In this same regard, according to the U.S. Department of Health and Human 
Services Administration of Aging, the percentage of older people that completed high 
school rose from 28% to 71% between 1970 and 2003.  Approximately 83% of the 
sample studied had completed a high school education, and taking into consideration that 
the recruitment process was between 1979 and 2003, it is possible to establish the this 
sample was highly educated compared with the general American population. 
An analysis of the association between potentially inappropriate medication and 
cognitive decline was attempted, with an attempt to define the number of PIM according 
to 2012 Beers criteria for each participant in order to obtain a number of PIM and use it 
as an exposure instead of polypharmacy. However, after thorough analysis of the data 
available, the way the drugs were coded did not allow for a drug-specific analysis, which 
is needed for a proper analysis of Potentially Inappropriate Medication or for 
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Anticholinergic Cognitive Burden scale.  Drugs were coded using the AHFS 
pharmacologic therapeutic classification, which was developed by the American Society 
of Health System Pharmacists to improve the organization of drug formularies in 
institutional or governmental settings.  The code allows a hierarchic classification in 4 
tier categories considering the pharmacological, therapeutical or chemical properties of 
the compound[61].  One of the disadvantages of this classification system is that some 
drugs can have multiple classes, which represent a problem when trying to analyze 
specific drugs.  In addition to the multiple classes per drug, the NMAPS used just the first 
3 tiers to code the name of the drugs, so instead of obtaining a drug name, the code only 
gives a classification, for example antibacterials, bile acid sequestrants or antiarrhythmic 
agents.  Therefore, the coding of the data did not allow for a deeper analysis of the drugs 
prescribed to the participants, which would have help to give some light regarding the 
utilization pattern of drugs among elderly population in America. 
A better classification system to use for coding drug names is the Anatomical 
Therapeutic Chemical (ATC) classification system.  This code was developed by the 
WHO Collaborating Centre For Drug Statistics Methodology to be use in drug utilization 
statistics[62].  For this reason, this code is the appropriate one to develop drug utilization 
studies. 
Among the limitations of the study, it is possible to point out that the population 
studied was predominantly white, female, and well educated, which makes this 
population very homogeneous and not necessarily generalizable to other populations in 
the U.S. or around the world.    
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MMSE was designed as a screening tool and therefore is a brief and fast tool to 
evaluate patients, which makes it a very good tool to apply in a research study; however 
it does not gives you a definitive diagnosis, which should be achieved by the application 
of several specific tests and the analysis of a trained professional.  Nevertheless, this does 
not invalidate the results of the study, MMSE is still a validated tool to detect alterations 
in cognitive performance, but it stresses the fact that for a deeper analysis of how drugs 
affect cognition, it would be important to perform a more specific study of cognitive 
function, for which obtaining specific diagnoses, differentiating the types of cognitive 
impairments or types of dementia may shed light on how to face the problems of patients 
suffering from these diseases. 
As mentioned before, polypharmacy also may have an impact on the ability to 
perform activities of daily living, which leads to a loss of independence.  For this reason 
it is important that future research not only study cognitive decline as an outcome, but 
also analyze how the exposure to drugs, measured as polypharmacy, PIM or other, affects 
the ability of elderly people to function as independent individuals.  Additionally, the 
study of changes in the different cognitive domains due to aging, and how drug 
utilization affects them is still a pending subject, which would help improve drug safety 
and quality of life in the growing older population.   
It is also important for future research to consider the use of validated and 
standardized tools when measuring cognitive and functional performance of elder 
individuals, rather than creating novel tools which lack validation in this population.  
Validated tools will give better quality results.  Finally, in order to obtain comparable and 
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generalizable results, future studies must carefully plan the recruitment strategies to 
obtain a representative sample of older people.   
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CONCLUSION 
The results obtained from the present study suggest that polypharmacy, Charlson 
comorbidity index, and the presence of APOE 4 allele negatively affect the performance 
of older adults on the MMSE.  Further studies are needed in order to establish the 
mechanism in which polypharmacy affects cognition, including the analysis of the impact 
of PIM and anticholinergic drugs on cognitive performance of older people.  
Additionally, the role of hypertension and anti-hypertensive treatment in cognitive 
performance should be further studied, considering that studies suggest that 
antihypertensive treatment could be an important tool to prevent cognitive decline.  
Finally, the present study further stresses the need of future characterization of the elderly 
population, from a demographic and health perspective, making special emphasis in the 
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TABLES 
Table 1: Demographic characteristics of studied population at baseline 
Variable N % 
Age  
≤ 70 years old 152 30.71 
71-80 years old 229 46.26 
More than 80 years old 114 23.03 




Men 208 36.36 




more than 16 years 207 36.19 
12-16 years 270 47.20 




White 314 88.45 
Hispanic 29 8.17 
Black 2 0.56 
Other 10 2.82 




Married 381 66.61 
Divorced 44 7.69 
Separated 4 0.70 
Single/Never married 19 3.32 




Independent 563 98.43 
Institution 9 1.57 
   
Currently working   
Yes 472 82.52 




Yes 331 64.90 
No 179 35.10 
Missing 62  
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Table 2: Health characteristics of the population studied 
 First Evaluation Last Evaluation 






















Polypharmacy (N, %)     
No polypharmacy 491 85.84 346 60.49 
Polypharmacy 81 14.16 226 39.51 











MCI (N, %)     
Present 26 4.55 40 6.99 
Absent 546 95.45 532 93.01 
 









Normal 279 51.76 279 54.39 
Overweight 203 37.66 180 35.09 
Obese 57 10.58 54 10.53 
Missing 33  59  
 
Depression (N, %)      
+ GDS 477 88.83 441 81.82 
- GDS 60 11.17 98 18.18 
Missing 35  33  
 
+ Diagnosis 24 4.20 31 5.42 
- Diagnosis 548 95.80 541 94.58 
 
Diabetes (N, %)    569   
+ Diagnosis 1 0.18 3 0.53 
-Diagnosis 567 99.82 566 99.47 
Missing 4  3  
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Hypertension (N, %)      
+ Diagnosis 161 28.35 196 34.45 
- Diagnosis 407 71.65 373 65.55 
Missing 4  3  
 
Charlson Comorbidity Index (N, %)     
0 349 60.56 256 44.99 
1 88 15.49 129 22.67 
≥2 136 23.94 184 32.34 
Missing 4  3  
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Table 3: Description of population by polypharmacy status at the last evaluation 
 No Polypharmacy Polypharmacy 2 
N % N % p-value 
Sex      
Male 139 40.17 69 30.53 0.02 
Female 207 59.83 157 69.47  
 
Education     
 
more than 16 years 127 36.71 80 35.4 0.59 
12-16 years 158 45.66 112 49.56  
12 or less years 61 17.63 34 15.04  
      
Body Mass Index      
Normal (<25) 176 57.52 103 49.76 0.14 
Overweight (25-30) 103 33.66 77 37.20  
Obese (>30) 27 8.82 27 13.04  
      
Diabetes      
+ Diagnosis 2 0.58 1 0.45 0.78 * 
- Diagnosis 343 99.42 223 99.55  
      
Depression      
+ Diagnosis 12 3.47 19 8.41 0.01 
- Diagnosis 334 96.53 207 91.59  
      
+GDS  268 82.97 173 80.09 0.40 
- GDS  55 17.03 43 13.31  
Missing 33     
      
Hypertension      
+ Diagnosis 78 22.61 118 52.68 <0.0001 
- Diagnosis 267 77.39 106 47.32  
Missing 3     
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Table 4: Description of population by MCI status at the last evaluation 
 No MCI MCI 2 
N % N % p-value 
Sex     0.12 
Male 183 35.5 19 47.5  
Female 343 64.5 21 52.2  
 
Education     0.62 
more than 16 years 191 35.9 16 40  
12-16 years 254 47.7 16 40  
12 or less years 87 16.4 8 20  
      
Body Mass Index     0.002* 
Normal (<25) 251 52.4 28 82.4  
Overweight (25-30) 176 36.7 4 11.8  
Obese (>30) 52 10.9 2 5.9  
      
Diabetes     0.8* 
+ Diagnosis 3 0.6 0 0  
- Diagnosis 527 99.4 39 100  
      
Depression     0.6 
+ Diagnosis 29 5.5 2 5  
- Diagnosis 503 94.5 38 95  
     0.16* 
+GDS  408 81.3 33 89.2  
- GDS  94 18.7 4 10.8  
Missing 33     
      
Hypertension     0.02 
+ Diagnosis 189 35.7 7 17.9  
- Diagnosis 341 64.3 32 82.1  
Missing 3     
      
Charlson Comorbidity Index    0.07 
0 245 46.2 11 28.2  
1 119 22.5 10 25.6  
≥2 166 31.3 18 46.2  
Missing 3     
* Fisher’s exact test 
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Table 5: Unadjusted associations between polypharmacy and measures of cognitive 
decline. 
 No Polypharmacya Polypharmacya P-value 
MMSE Score    
Baselineb 28.33±2.26 28.85±1.53 0.009 
Finalc 27.80±3.22 28.66±2.19 0.0002 
 
MMSE Score deltad -0.35±3.27 -0.08±0.40 0.28 
 
MCI (baseline)   0.017e 
Absent 465 81  
Present 26 0  
 
MCI (final)   
 
0.02 
Absent 315 217  
Present 31 9  
a Polypharmacy is defined as the concomitant use of 5 or more medications 
b at the moment the first MMSE performed. 
c at the moment of the last MMSE performed. 
d Change in MMSE score from baseline to final evaluation. 
e Fisher’s exact test 
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Table 6: Unadjusted associations between change in polypharmacy status and MMSE 
score.  
Variable 
No Change in 
Polypharmacy Statusa 
Change in Polypharmacy 
Statusb p-value 
MMSE Score (final) 27.97±3.06 28.60±2.32 0.0079 
MMSE Score delta -0.31±3.09 -0.06±2.63 0.32 
a No change in polypharmacy status includes those participants who did not change their 
polypharmacy status during the follow up and those who changed from polypharmacy to 
no polypharmacy. 
b Change in polypharmacy status only includes those participants who changed from no 
polypharmacy to polypharmacy. 
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Table 7: Mixed multivariable linear model results examining the effect of 
polypharmacy on MMSE score. N=439 
Covariates β SEa P-value 
Polypharmacy -0.11 0.092 0.23 
Gender    
Male -0.15 0.10 0.14 
Female 0   
Age at baseline -0.045 0.0079 <0.0001 
Charlson comorbidity index             
≥2 -0.22 0.11 0.043 
  1 -0.065 0.13 0.62 
  0 0   
ApoE4 allele -0.17 0.10 0.099 
BMI    
Obese 0.048 0.15 0.76 
Overweight 0.16 0.096 0.096 
Normal 0   
Hypertension  0.22 0.10 0.033 
Years since baseline -0.024 0.016 0.13 
MMSE score at baseline 0.34 0.027 0.0001 
a SE=Standard error 
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Table 8: Mixed multivariable linear model results examining the effect of 
polypharmacy on the change in MMSE score. N=439 
Covariates β SEa P-value 
Polypharmacy -0.12 0.092 0.20 
Gender    
Male -0.14 0.10 0.17 
Female 0   
Age at baseline -0.047 0.0079 <0.0001 
Charlson Comorbidity Index    
≥2 -0.23 0.10 0.031 
  1 -0.065 0.13 0.62 
  0 0   
ApoE 4 allele -0.17 0.10 0.093 
BMI     
Obese 0.046 0.15 0.77 
Overweight 0.16 0.096 0.10 
Normal 0   
Hypertension  0.22 0.10 0.031 
Years since baseline -0.024 0.016 0.14 
MMSE score at baseline -0.67 0.027 0.0001 




 41  
Table 9: Multivariable GEE model results examining the effect of 





 Polypharmacy 1.94 (0.40, 9.43) 
 Sex   
 Male 2.50 (0.52, 12.12) 
 Female (Reference) 1.0 (1.0, 1.0) 
 Age at baseline 1.11 (0.98, 1.25) 
 Charlson Comorbidity Index   
 ≥2 1.4 (0.21, 9.26) 
   1 0.90 (0.05, 3.32) 
   0 (Reference) 1.0 (1.0, 1.0) 
 ApoE 4 allele 2.18 (0.48, 9.96) 
 BMI   
 Obese 0.78 (0.08, 7.29) 
 Overweight 0.21 (0.04, 1.09) 
 Normal (Reference) 1.0 (1.0, 1.0) 
 Hypertension  0.12 (0.02, 0.65) 
 Years Since baseline 1.27 (0.91, 1.78) 
 First MMSE score -0.40 (0.30, 0.52) 
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